Human IgG (H&L) Antibody Biotin Conjugated

SKU: orb347348

Description

Human IgG (H&L) antibody (Biotin)

Images & Validation

• Tested Applications: ELISA, IHC, WB
• Dilution range: ELISA: 1:20,000 - 1:100,000, IHC: 1:1,000 - 1:5,000, WB: 1:2,000 - 1:10,000
• Reactivity: Human
• Application Notes:
  This product has been assayed against 1.0 ug of Human IgG in a standard capture ELISA using Peroxidase Conjugated Streptavidin #S000-03 and ABTS (2,2’-azino-bis-[3-ethylbenthiazoline-6-sulfonic acid]) as a substrate for 30 minutes at room temperature. A working dilution of 1:4,000 to 1:20,000 of the reconstitution concentration is suggested for this product.

Key Properties

• Antibody Type: Secondary Antibody
• Host: Gallus
• Clonality: Polyclonal
• Isotype: IgG
• Immunogen: Human IgG whole molecule
• Purity: This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-biotin, anti-Chicken Serum, Human IgG and Human Serum.
• Conjugation: Biotin

Storage & Handling

• Storage: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
• Form/Appearance: Lyophilized
• Buffer/Preservatives: 0.01% (w/v) Sodium Azide
• Concentration: 1.0 mg/mL
• Disclaimer: For research use only

Alternative Names

Chicken Anti Human IgG Antibody Biotin Conjugate, Chicken Anti-Human IgG Biotin conjugated Antibody

IgG responses to SARS-CoV-2 N protein variants. Four SARS-CoV-2 N protein variants were fabricated on to the microarray surface, including full-length N protein, core domain (amino acids 44-364), C-terminal domain (CTD) (amino acids 248-365) and N terminal domain (NTD) (amino acids 24-181). The IgG response from the plasma of 8 colorectal cancer (C) and 7 convalescent COVID-19 (P) patients were assessed for the 4 variants.

Linearity of signal as a function of serum dilution on the microarray platform. Panels A & B show data for the N core domains, N-terminal domain and C-terminal domain, for patients 189 and 192 respectively. Panels C & D show data for peptides 6, 8 & 16, for patients 189 and 192 respectively. x-axis shows the serum dilutions for each measurement. y-axis units are relative fluorescence units (RFU).